- Home
- PTGX vs AMRX Comparison
PTGX vs AMRX Comparison
Compare PTGX & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- AMRX
- Stock Information
- Founded
- PTGX 2006
- AMRX 2002
- Country
- PTGX United States
- AMRX United States
- Employees
- PTGX N/A
- AMRX N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- AMRX Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- AMRX Health Care
- Exchange
- PTGX Nasdaq
- AMRX Nasdaq
- Market Cap
- PTGX 3.7B
- AMRX 2.9B
- IPO Year
- PTGX 2016
- AMRX N/A
- Fundamental
- Price
- PTGX $61.69
- AMRX $9.74
- Analyst Decision
- PTGX Strong Buy
- AMRX Strong Buy
- Analyst Count
- PTGX 9
- AMRX 4
- Target Price
- PTGX $70.44
- AMRX $12.00
- AVG Volume (30 Days)
- PTGX 925.0K
- AMRX 1.5M
- Earning Date
- PTGX 11-06-2025
- AMRX 11-07-2025
- Dividend Yield
- PTGX N/A
- AMRX N/A
- EPS Growth
- PTGX N/A
- AMRX N/A
- EPS
- PTGX 0.80
- AMRX 0.01
- Revenue
- PTGX $209,180,000.00
- AMRX $2,852,914,000.00
- Revenue This Year
- PTGX N/A
- AMRX $9.56
- Revenue Next Year
- PTGX $248.17
- AMRX $6.27
- P/E Ratio
- PTGX $73.55
- AMRX $883.95
- Revenue Growth
- PTGX N/A
- AMRX 9.81
- 52 Week Low
- PTGX $33.31
- AMRX $6.69
- 52 Week High
- PTGX $61.89
- AMRX $10.34
- Technical
- Relative Strength Index (RSI)
- PTGX 61.67
- AMRX 59.37
- Support Level
- PTGX $57.90
- AMRX $9.57
- Resistance Level
- PTGX $60.40
- AMRX $10.34
- Average True Range (ATR)
- PTGX 2.47
- AMRX 0.24
- MACD
- PTGX 0.06
- AMRX -0.05
- Stochastic Oscillator
- PTGX 94.34
- AMRX 41.67
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.